Inventiva Stock Forecast, Price & News

+1.03 (+7.04 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume22,150 shs
Average Volume27,636 shs
Market Capitalization$605.33 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Inventiva logo

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.44 out of 5 stars

Medical Sector

671st out of 2,100 stocks

Biotechnology Industry

1st out of 90 stocks

Analyst Opinion: 3.3Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Inventiva (NYSE:IVA) Frequently Asked Questions

Is Inventiva a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Inventiva stock.
View analyst ratings for Inventiva
or view top-rated stocks.

What stocks does MarketBeat like better than Inventiva?

Wall Street analysts have given Inventiva a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inventiva wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for IVA?

5 analysts have issued 12 month price targets for Inventiva's shares. Their forecasts range from $18.00 to $38.00. On average, they expect Inventiva's share price to reach $27.33 in the next year. This suggests a possible upside of 74.4% from the stock's current price.
View analysts' price targets for Inventiva
or view top-rated stocks among Wall Street analysts.

Who are Inventiva's key executives?

Inventiva's management team includes the following people:
  • Mr. Frederic Cren, Co-Founder, CEO & Chairman (Age 55, Pay $470.67k)
  • Dr. Pierre Broqua, Co-Founder, Chief Scientific Officer, Deputy CEO & Director (Age 59, Pay $357.06k)
  • Mr. Jean Volatier, Chief Financial Officer (Age 57)
  • Mr. Nicolas Gueugnon, Legal Director
  • Ms. Nathalie Harroy, Head of HR
  • Dr. Olivier Lacombe PH.D., Head of Pharmacokinetics
  • Dr. Christian Montalbetti PH.D., Head of Chemistry
  • Dr. Irena Konstantinova, Head of Biology & Pharmacology
  • Dr. Kristina Meyer, Head of Bus. Devel.
  • Dr. Michael Cooreman, Chief Medical Officer (Age 63)

Who are some of Inventiva's key competitors?

What other stocks do shareholders of Inventiva own?

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

What is Inventiva's stock symbol?

Inventiva trades on the New York Stock Exchange (NYSE) under the ticker symbol "IVA."

Who are Inventiva's major shareholders?

Inventiva's stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (0.28%), Credit Suisse AG (0.08%), Millennium Management LLC (0.05%) and Citadel Advisors LLC (0.04%).

Which major investors are selling Inventiva stock?

IVA stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, and Millennium Management LLC.

Which major investors are buying Inventiva stock?

IVA stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, and Credit Suisse AG.

How do I buy shares of Inventiva?

Shares of IVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inventiva's stock price today?

One share of IVA stock can currently be purchased for approximately $15.67.

How much money does Inventiva make?

Inventiva has a market capitalization of $605.33 million.

How many employees does Inventiva have?

Inventiva employs 88 workers across the globe.

What is Inventiva's official website?

The official website for Inventiva is www.inventivapharma.com.

How can I contact Inventiva?

The company can be reached via phone at 33 3 80 44 75 00.

This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.